ArticleRegenerative biomaterials2025
Natural product-based nano-antioxidant for the treatment of acute pancreatitis.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.Discover nano · 2026Review
- Functional recovery after spinal cord injury through neuroprotection by lipoic acid-loaded hollow mesoporous Prussian blue nanozymes.Regenerative biomaterials · 2026Article
- Nanotherapy for Pancreatitis: From Single-Cell Targeting Toward Multicellular-Coordinated Regulation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is a potentially highly fatal inflammatory disease characterized by the generation of high level of reactive oxygen species (ROS) of mass recruited inflammatory macrophages in pancreatic tissue. Many natural product antioxidants have been explored to treat AP due to their superiority in biosafety while the therapeutic application is restricted by their low ROS elimination as well as the rapid metabolism caused by small molecular weight and fast absorption. Herein, a new natural product-based nano-antioxidant (FA@zein-CS) that can overcome these problems was developed for the treatment of AP by encapsulating ferulic acid (FA) into the zein based nanoparticles and then hybridizing of chondroitin sulfate (CS). The FA@zein-CS would not only efficiently target to the inflamed pancreatic tissue by the specific binding of CS to CD44, but also effectively initiate the release of FA and zein degradation product in response to intracellular pH/GSH/ROS to achieve synergistic antioxidant effect. In addition, thanks to the fact that all components were derived from natural products, the FA@zein-CS held the excellent biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.